Movement Alert｜Hengrui Medicine Falls 3.19% in Regular Trading, Pharmaceutical Sector Broadly Weak Despite Pipeline Progress

Market Focus10:14

On July 17, Hengrui Medicine fell 3.19% in regular trading, trading at 55.75 HKD/share, with turnover of approximately 68.17 million HKD. The decline came amid broad-based weakness across the pharmaceutical sector.

The Pharmaceuticals sector where Hengrui belongs experienced significant selling pressure, with major peers declining sharply: Asymchem down 7.69%, China Biopharmaceutical down 5.32%, Luye Pharma down 4.5%, CSPC Pharmaceutical down 4.3%, and Hansoh Pharmaceutical down 3.56%. The sector-wide retreat overshadowed recent positive pipeline developments, including the company's July 16 approval to conduct Phase III clinical trials for HRS9531 injection in obese patients with knee osteoarthritis, building on cumulative R&D investment of approximately 701 million yuan. Lingering pressure from the FDA's third Complete Response Letter for camrelizumab combination therapy, disclosed on July 10, citing cGMP manufacturing facility inspection issues, may also continue to weigh on sentiment despite the company clarifying no concerns were raised regarding clinical efficacy or safety data.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128727462?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128727462","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Falls 3.19% in Regular Trading, Pharmaceutical Sector Broadly Weak Despite Pipeline Progress","media":"Market Focus","content":"<p><p>On July 17, Hengrui Medicine fell 3.19% in regular trading, trading at 55.75 HKD/share, with turnover of approximately 68.17 million HKD. The decline came amid broad-based weakness across the pharmaceutical sector.</p><p>The Pharmaceuticals sector where Hengrui belongs experienced significant selling pressure, with major peers declining sharply: Asymchem down 7.69%, China Biopharmaceutical down 5.32%, Luye Pharma down 4.5%, CSPC Pharmaceutical down 4.3%, and Hansoh Pharmaceutical down 3.56%. The sector-wide retreat overshadowed recent positive pipeline developments, including the company's July 16 approval to conduct Phase III clinical trials for HRS9531 injection in obese patients with knee osteoarthritis, building on cumulative R&D investment of approximately 701 million yuan. Lingering pressure from the FDA's third Complete Response Letter for camrelizumab combination therapy, disclosed on July 10, citing cGMP manufacturing facility inspection issues, may also continue to weigh on sentiment despite the company clarifying no concerns were raised regarding clinical efficacy or safety data.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Falls 3.19% in Regular Trading, Pharmaceutical Sector Broadly Weak Despite Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Falls 3.19% in Regular Trading, Pharmaceutical Sector Broadly Weak Despite Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, Hengrui Medicine fell 3.19% in regular trading, trading at 55.75 HKD/share, with turnover of approximately 68.17 million HKD. The decline came amid broad-based weakness across the pharmaceutical sector.</p><p>The Pharmaceuticals sector where Hengrui belongs experienced significant selling pressure, with major peers declining sharply: Asymchem down 7.69%, China Biopharmaceutical down 5.32%, Luye Pharma down 4.5%, CSPC Pharmaceutical down 4.3%, and Hansoh Pharmaceutical down 3.56%. The sector-wide retreat overshadowed recent positive pipeline developments, including the company's July 16 approval to conduct Phase III clinical trials for HRS9531 injection in obese patients with knee osteoarthritis, building on cumulative R&D investment of approximately 701 million yuan. Lingering pressure from the FDA's third Complete Response Letter for camrelizumab combination therapy, disclosed on July 10, citing cGMP manufacturing facility inspection issues, may also continue to weigh on sentiment despite the company clarifying no concerns were raised regarding clinical efficacy or safety data.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1128727462","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128727462","pubTimestamp":1784254499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, Hengrui Medicine fell 3.19% in regular trading, trading at 55.75 HKD/share, with turnover of approximately 68.17 million HKD. The decline came amid broad-based weakness across the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"走势提醒|恒瑞医药常规交易下跌3.19%，尽管管道取得进展，医药板块普遍疲软","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On July 17, Hengrui Medicine fell 3.19% in regular trading, trading at 55.75 HKD/share, with turnover of approximately 68.17 million HKD. The decline came amid broad-based weakness across the pharmaceutical sector.The Pharmaceuticals sector where Hengrui belongs experienced significant selling pressure, with major peers declining sharply: Asymchem down 7.69%, China Biopharmaceutical down 5.32%, Luye Pharma down 4.5%, CSPC Pharmaceutical down 4.3%, and Hansoh Pharmaceutical down 3.56%. The sector-wide retreat overshadowed recent positive pipeline developments, including the company's July 16 approval to conduct Phase III clinical trials for HRS9531 injection in obese patients with knee osteoarthritis, building on cumulative R&D investment of approximately 701 million yuan. Lingering pressure from the FDA's third Complete Response Letter for camrelizumab combination therapy, disclosed on July 10, citing cGMP manufacturing facility inspection issues, may also continue to weigh on sentiment despite the company clarifying no concerns were raised regarding clinical efficacy or safety data.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128727462","isCrawlerRequest":true}